Shire Pharmaceuticals will buy Roberts, creating new force in specialty drugs
Article Abstract:
Shire Pharmaceuticals Group PLC has reached an agreement to purchase Roberts Pharmaceutical Corp. The acquisition will have a value of $1 billion (952 million euros). Both companies are rapidly-expanding entities. The acquisition will form a powerful new entity in the specialty pharmaceutical industry. The deal could mean the beginning of a series of consolidations within the industry.
Comment:
Shire Pharmaceuticals Group to purchase Roberts Pharmaceutical for $1 billion
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Canada regulators may hold up deal by Shire, BioChem
Article Abstract:
The proposed merger of Shire Pharmaceuticals Group PLC and BioChem Inc. is expected to be approved by both companies' shareholders. However, the Ministry of Industry Canada is withholding approval of the deal for regulatory concerns.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Bayer anticipates stagnant sales in 1999. Bayer's operating earnings fell 45% in second quarter. Sales at Bayer fell 2.6% in 1999, but net rose 24%
- Abstracts: Ford beats expectations with second-quarter net. Ford earnings dropped sharply in the 4th quarter. Ford's net falls in wake of recall
- Abstracts: The dealer association as brand. Roger reconnects to Gee Jeffery. Effem hands $11M to MediaVest
- Abstracts: Schering may buy remaining stake in Aventis unit. Bayer plans to buy unit from Aventis for 5.5 billion euros
- Abstracts: Ahold's net rose 41% in quarter. VNU plans to make bid for ratings firm Nielsen. Amsterdam Exchange tightens listing rules